NeoTract
NeoTract was a privately-held medical device company founded in 2004 that developed and commercialized the FDA-cleared UroLift System, a minimally invasive transurethral treatment for lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). Teleflex Incorporated acquired NeoTract for up to $1.1 billion in October 2017; the UroLift product line now lives under Teleflex at urolift.com. Surfaced as a portfolio company of NEA. This is a physical medical-device business with no public developer, API, or SDK surface; the neotract.com domain no longer resolves.
NeoTract is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Health, MedTech, and Medical.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API